TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30411114

Group type: EXPERIMENTAL
Intervention: Cavity treated with catalase after external bleaching and then filled with composite resin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Composite resin filling immediately after external bleaching
Number of subjects: 40

Group type: COMPARATOR
Intervention: Immersed in artificial saliva for 3 weeks after external bleaching, then filling with composite resin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Direct composite resin filling without bleaching
Number of subjects: 40
Study: 26142456

Group type: EXPERIMENTAL
Intervention: High altitude hypoxia (5400 m)
Number of subjects: 39
Study: 23988398

Group type: EXPERIMENTAL
Intervention: Standard care (blinded random allocation to trial treatment or placebo)
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: Baseline PEFR, baseline heart rate, other serious illness, PEFR change, heart rate change
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: Baseline PEFR, baseline heart rate, baseline respiratory rate, other serious illness, PEFR change, heart rate change
Number of subjects: 1084
Study: 22264599

Group type: EXPERIMENTAL
Intervention: Cognitive adaptation training combined with assertive community treatment (CAT+ACT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Assertive community treatment alone (ACT)
Number of subjects: 62
Study: 19846267

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Valacyclovir plus Prednisolone
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study: 17211096

Group type: EXPERIMENTAL
Intervention: ED-71 treatment for 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ED-71 treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15526112

Group type: EXPERIMENTAL
Intervention: Electrogalvanic stimulation (EGS) twice a week
Number of subjects: 53

Group type: COMPARATOR
Intervention: Local injection of 40-mg triamcinolone acetonide mix with 1 ml 2% lidocaine
Number of subjects: 53
Study: 11564134

Group type: EXPERIMENTAL
Intervention: Levocetirizine (10 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cetirizine (as racemate)
Number of subjects: 24
Study: 9784078

Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Caffeinated beverages
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tea
Number of subjects: 19

Group type: COMPARATOR
Intervention: Water (placebo)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Coffee (100 mg caffeine)
Number of subjects: 19
Study: 7843964

Group type: EXPERIMENTAL
Intervention: Salt water baths with 15% synthetic Dead Seas salt (Psorisal)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3% NaCl solution baths
Number of subjects: 40
Study: 3152422

Group type: EXPERIMENTAL
Intervention: IV sodium nitroprusside
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside with oral captopril pretreatment
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: IV nitroglycerin
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3
Study: 31820008

Group type: EXPERIMENTAL
Intervention: Swing door technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 60
Study: 30131382

Group type: EXPERIMENTAL
Intervention: ASITN/SIR collateral score assessment by 19 observers
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dichotomized score for collateral assessment
Number of subjects: 19
Study: 28985328

Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood pressure target <120 mm Hg)
Number of subjects: 2488

Group type: COMPARATOR
Intervention: Standard treatment (systolic blood pressure target <140 mm Hg)
Number of subjects: 2488

Group type: EXPERIMENTAL
Intervention: Overall model (both treatment arms)
Number of subjects: 2488
Study: 25352300

Group type: EXPERIMENTAL
Intervention: lamivudine plus adefovir dipivoxil (ADV) combination therapy (COMBO)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: lamivudine optimization strategy (OPTIMIZE)
Number of subjects: 358

Group type: COMPARATOR
Intervention: lamivudine monotherapy (MONO)
Number of subjects: 358

Group type: COMPARATOR
Intervention: lamivudine monotherapy (MONO) with early virological response
Number of subjects: 358
Study: 23314393

Group type: EXPERIMENTAL
Intervention: 20 mg amphetamine (AMPH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22283037

Group type: EXPERIMENTAL
Intervention: Integrated Management of Neonatal and Childhood Illness (IMNCI)
Number of subjects: 1102573

Group type: COMPARATOR
Intervention: Control districts
Number of subjects: 1102573
Study: 19772869

Group type: EXPERIMENTAL
Intervention: Eszopiclone (ESZ)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 17186003

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 16036080

Group type: COMPARATOR
Intervention: Placebo-controlled trials
Number of subjects: 0
Study: 11928585

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (75 g)
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Fasting glycemia according to ADA recommendation
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test and glycemia at 120 min exceeding 11.1 mmol/l
Number of subjects: 6000
Study: 9328501

Group type: EXPERIMENTAL
Intervention: Psychological debriefing (PD)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 133
Study: 15125277

Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (no steroids)
Number of subjects: 82
Study: 2877576

Group type: EXPERIMENTAL
Intervention: 10 mg intravenous famotidine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 20 mg intravenous famotidine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 20 mg oral famotidine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30168257

Group type: EXPERIMENTAL
Intervention: Nav1 module
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: For1 module
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: ERM1 module
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: ERM2 module
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vit1 module
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vit2 module
Number of subjects: 21
Study: 29910118

Group type: EXPERIMENTAL
Intervention: Centralized reminder/recall for vaccination
Number of subjects: 50000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50000
Study: 27514161

Group type: EXPERIMENTAL
Intervention: Laparoscopic Assisted Vaginal Hysterectomy (LAVH)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Vaginal Hysterectomy (VH)
Number of subjects: 187
Study: 25443650

Group type: EXPERIMENTAL
Intervention: Tilt table standing, electrical stimulation and ankle splinting
Number of subjects: 36

Group type: COMPARATOR
Intervention: Tilt table standing alone
Number of subjects: 36
Study: 21914242

Group type: EXPERIMENTAL
Intervention: Minimal psychological intervention (MPI)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 361
Study: 20374547

Group type: EXPERIMENTAL
Intervention: Method 1 (preprocedure measurement using CXR)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Method 2 (preprocedure measurement using CXR)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Method 1 (preoperative supine CXR)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Method 2 (preoperative supine CXR)
Number of subjects: 291
Study: 18165459

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 16159618

Group type: EXPERIMENTAL
Intervention: ASHMI group (oral ASHMI capsules and prednisone placebo tablets)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Prednisone group (oral prednisone tablets and ASHMI placebo capsules)
Number of subjects: 91
Study: 12669132

Group type: EXPERIMENTAL
Intervention: High dose of n-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: High dose of n-3 PUFAs
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Additional statin treatment
Number of subjects: 300
Study: 10550467

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg once daily for 1 year
Number of subjects: 1908

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1908
Study: 8727863

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg twice daily
Number of subjects: 398

Group type: COMPARATOR
Intervention: Sulfadiazine 500 mg/Trimethoprim 160 mg twice daily
Number of subjects: 398
Study: 8348278

Group type: EXPERIMENTAL
Intervention: Active laser treatment (CB Medico Master III 830 nm Ga As AL diode)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Dummy laser treatment
Number of subjects: 35
Study: 3528278

Group type: EXPERIMENTAL
Intervention: Normal saline plus hydrocortisone (100 mg daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal saline (1 l/day)
Number of subjects: 13
Study: 29239772

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study: 27367723

Group type: EXPERIMENTAL
Intervention: Sodium‐bicarbonated mineral water (BW)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control mineral water low in mineral content (CW)
Number of subjects: 64
Study: 23484910

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with virgin olive oil (MED + VOO)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts (MED + nuts)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Control low-fat diet
Number of subjects: 564
Study: 21934310

Group type: EXPERIMENTAL
Intervention: Nonsmoking model pressuring not to smoke
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Nonsmoking peers verbally pressuring not to smoke
Number of subjects: 59

Group type: COMPARATOR
Intervention: Heavy‐smoking model not using any pressure
Number of subjects: 59

Group type: COMPARATOR
Intervention: Nonsmoking peers not verbally pressuring
Number of subjects: 59
Study: 19608816

Group type: EXPERIMENTAL
Intervention: Modified method using a retractable carinal hook (hook group, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional method (conventional group, n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modified method using a retractable carinal hook (hook group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional method (conventional group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 17512232

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 0.019 mg kg(‐1) day(‐1) for 6 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (abstinent AAS users)
Number of subjects: 48
Study: 15459211

Group type: EXPERIMENTAL
Intervention: Doxorubicin 60 mg/m² plus cisplatin 50 mg/m² every 3 weeks
Number of subjects: 281

Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m²
Number of subjects: 281
Study: 11441776

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9210675

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally every 12 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 mg intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (both routes)
Number of subjects: 12
Study: 8135686

Group type: EXPERIMENTAL
Intervention: Educational video shown to randomly assigned group of Veteran hospital psychiatric patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall attitudes towards ECT in all three groups (psychiatric patients, non-psychiatric patients, general hospital patients)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Media influence on attitudes
Number of subjects: 0
Study: 3689614

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.8 mg (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: i.m. papaveretum 10 mg (group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control gastric emptying rates (before surgery)
Number of subjects: 20
Study: 29451991

Group type: EXPERIMENTAL
Intervention: βHB (d‐β‐hydroxybutyrate) beverage (11.38 g)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PLA) beverage
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: βHB (d‐β‐hydroxybutyrate) beverage
Number of subjects: 15
Study: 26655163

Group type: EXPERIMENTAL
Intervention: CP‐Trp mixture
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: CP+Trp mixture
Number of subjects: 29

Group type: COMPARATOR
Intervention: CP‐Trp
Number of subjects: 29
Study: 24610088

Group type: EXPERIMENTAL
Intervention: HF scissors (HF+ group)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (CONV)
Number of subjects: 35
Study: 22456803

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics
Number of subjects: 84

Group type: COMPARATOR
Intervention: Supportive treatment only
Number of subjects: 84
Study: 20130660

Group type: EXPERIMENTAL
Intervention: Inulin
Number of subjects: 12

Group type: COMPARATOR
Intervention: 56HFCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: 80HFCS
Number of subjects: 12
Study: 18687261

Group type: EXPERIMENTAL
Intervention: Various health promotion interventions based on theories such as Transtheoretical Model, Motivational Interviewing, Social Learning and Social Cognitive Theory, Theory of Planned Behavior, and Cognitive Behavioral Theory
Number of subjects: 0
Study: 16552319

Group type: EXPERIMENTAL
Intervention: Community-driven strategies targeting access to healthcare, health and wellness, screening, and tobacco use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based system for collecting process data and random telephone surveys
Number of subjects: 0
Study: 12523893

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 681

Group type: COMPARATOR
Intervention: CMV retinitis
Number of subjects: 681
Study: 11193281

Group type: EXPERIMENTAL
Intervention: Antithrombin III concentrates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protein C and tissue factor-pathway inhibitor
Number of subjects: 0
Study: 9033197

Group type: EXPERIMENTAL
Intervention: multidrug regimens
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: maximal regimen including daily clofazimine
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: prednisolone
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: thalidomide
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: maximal regimens including daily rifampicin
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: measurements of weight and blood pressure
Number of subjects: 215
Study: 1670744

Group type: EXPERIMENTAL
Intervention: Doxazosin (4.7 mg daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Prazosin (6.7 mg daily)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 42
Study: 6138086

Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg p.o.)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oxazepam (15 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30944048

Group type: EXPERIMENTAL
Intervention: Force-feeding
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control (free feeding)
Number of subjects: 500
Study: 28355198

Group type: EXPERIMENTAL
Intervention: F130 (130 mg of OPN/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: F65 (65 mg of OPN/L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SF (Standard Formula)
Number of subjects: 0
Study: 25643897

Group type: EXPERIMENTAL
Intervention: Resistance training prior to aerobic training (RA, n=10)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Resistance training after aerobic training (AR, n=11)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both RA and AR groups
Number of subjects: 21
Study: 25151265

Group type: EXPERIMENTAL
Intervention: Ablation or silencing of GABAergic neurons or disruption of metabotropic GABA receptor 1 and 2 (GABA B R1/2) signaling in astrocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Developmental depletion of astrocytic GABA B R1/2 signaling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ablation of astrocytes
Number of subjects: 0
Study: 22300419

Group type: EXPERIMENTAL
Intervention: Midazolam pharmacokinetics model based on infants, toddlers, and adults (model 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam pharmacokinetics model based on children and adolescents (model 2)
Number of subjects: 0
Study: 19240698

Group type: COMPARATOR
Intervention: NSAID-related injury prevention guidelines
Number of subjects: 0

Group type: COMPARATOR
Intervention: COX-2 inhibitors
Number of subjects: 0
Study: 17721040

Group type: EXPERIMENTAL
Intervention: Existing drugs (e.g., non‐steroidal anti‐inflammatory drugs, vitamins, and imatinib mesylate)
Number of subjects: 0
Study: 16586188

Group type: EXPERIMENTAL
Intervention: 4 micrograms 1‐alpha‐hydroxyvitamin D(2) (1‐alpha D(2)) administered daily for 24 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo administered daily for 24 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 4 micrograms 1‐alpha D(2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12802451

Group type: EXPERIMENTAL
Intervention: Natural biocorrector Namivit
Number of subjects: 0
Study: 9858106

Group type: EXPERIMENTAL
Intervention: Insulin treatment (n = 18)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sulfonylurea treatment (n = 16)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy controls (n = 20)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Patients (n = 38)
Number of subjects: 38
Study: 7890127

Group type: EXPERIMENTAL
Intervention: Parenteral amino acid preparation causing high plasma amino acid levels
Number of subjects: 27

Group type: COMPARATOR
Intervention: Parenteral amino acid preparation with normal plasma aminogram levels
Number of subjects: 27
Study: 2212504

Group type: COMPARATOR
Intervention: Timoptol 0.5% alone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Timoptol 0.5%-Pilocarpine 2% (timpilo 2)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Timoptol 0.5%-Pilocarpine 4% (timpilo 4)
Number of subjects: 3
Study: 341946

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 30304382

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (14-week lifestyle intervention)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Baseline WBIS scores
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Participant race and WBIS scores interaction
Number of subjects: 133
Study: 28185708

Group type: EXPERIMENTAL
Intervention: β‐TCP
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: β‐TCP + autogenous bone graft (1:1)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Autogenous bone graft
Number of subjects: 33
Study: 26280156

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MMF) 0.1% ointment, applied once daily for 5 days per week for 4 weeks, then on alternate days for 4 weeks, then twice weekly for 4 weeks (group A)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MMF) 0.1% ointment, applied for five consecutive days per week for the entire treatment duration (group B)
Number of subjects: 64
Study: 23712068

Group type: EXPERIMENTAL
Intervention: PEEP 10 cmH2O
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PEEP 5 cmH2O
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no PEEP)
Number of subjects: 60
Study: 21855160

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Medical Nutrition Therapy (MNT)
Number of subjects: 44
Study: 18196202

Group type: EXPERIMENTAL
Intervention: PPN-DBS (25 Hz)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: STN-DBS (185 Hz)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PPN-DBS plus STN-DBS
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (n = 9)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: DBS (both PPN and STN)
Number of subjects: 6
Study: 16021530

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation at 80 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation at 200 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation at 400 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 12548078

Group type: EXPERIMENTAL
Intervention: Folic acid (10 mg/d) for 14 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11132252

Group type: EXPERIMENTAL
Intervention: Intravenous porcine secretin
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 8936626

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 101
Study: 1390473

Group type: EXPERIMENTAL
Intervention: Endocervical sampling with the Kevorkian curette
Number of subjects: 100

Group type: COMPARATOR
Intervention: Endocervical sampling with the Medscand endocervical brush
Number of subjects: 100
Study: 3847486

Group type: EXPERIMENTAL
Intervention: Cefotaxime (50 mg/kg/dose every 6 hours)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard therapy (ampicillin and chloramphenicol in standard doses)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cefotaxime and Standard therapy
Number of subjects: 50
Study: 31275607

Group type: EXPERIMENTAL
Intervention: Nurse-led comorbidity counselling
Number of subjects: 769
Study: 29558837

Group type: EXPERIMENTAL
Intervention: Introduction of eggs into infants' diets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative research and social marketing component
Number of subjects: 0